Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01409993 · ClinicalTrials.gov registry record · Phase 4
Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis
A Phase 4 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT01409993: Clinical Trial Phase 4 study, sponsored by Vanderbilt University.
NCT01409993 is a Phase 4 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 78 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01409993, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of chronic PDE5 inhibitor therapy on glucose metabolism in persons with prediabetes.
Primary Outcome
in the group of subjects undergoing hyperglycemic clamp (Aim 1)
Interventions
- DRUG Placebo
- DRUG Sildenafil
- DIAGNOSTIC_TEST Hyperglycemic clamp
- DIAGNOSTIC_TEST Euglycemic clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2011-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 4 |
Why NCT01409993 stopped before completion
NCT01409993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01409993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01409993 about?
NCT01409993 is a clinical study titled "Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis". The purpose of this study is to determine the effect of chronic PDE5 inhibitor therapy on glucose metabolism in persons with prediabetes.
What is the current status of trial NCT01409993?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2011-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01409993?
The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG), Hyperglycemic clamp (DIAGNOSTIC_TEST), Euglycemic clamp (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01409993?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01409993's enrollment target sits among peer trials
78 982nd of 2000 higher than 1,012 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia